TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12066244

Group type: EXPERIMENTAL
Intervention: 240 g of oral barium tracer
Number of subjects: 119

Group type: COMPARATOR
Intervention: 60 g of oral barium tracer
Number of subjects: 119

Group type: COMPARATOR
Intervention: 150 g of oral barium tracer
Number of subjects: 119

Group type: COMPARATOR
Intervention: Control group (no barium tracer)
Number of subjects: 119
Study: 10434165

Group type: EXPERIMENTAL
Intervention: Granisetron 40 mg kg‐1
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Dexamethasone 150 mg kg‐1
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Granisetron 40 mg kg‐1 plus Dexamethasone 150 mg kg‐1
Number of subjects: 150
Study: 11727685

Group type: EXPERIMENTAL
Intervention: Room-temperature buffered lidocaine
Number of subjects: 34

Group type: COMPARATOR
Intervention: Warm plain lidocaine
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Warm buffered lidocaine
Number of subjects: 34

Group type: COMPARATOR
Intervention: Room-temperature buffered lidocaine (Part II)
Number of subjects: 34
Study: 1721881

Group type: EXPERIMENTAL
Intervention: Nd:YAG laser
Number of subjects: 34

Group type: COMPARATOR
Intervention: 3% polidocanol injection
Number of subjects: 34
Study: 7045090

Group type: EXPERIMENTAL
Intervention: Nomifensine
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 33
Study: 30862583

Group type: EXPERIMENTAL
Intervention: Template-guided CPS placement
Number of subjects: 4

Group type: COMPARATOR
Intervention: Freehand CPS placement
Number of subjects: 4
Study: 28936612

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided tracheal intubation
Number of subjects: 266

Group type: COMPARATOR
Intervention: Fiberscope-guided tracheal intubation
Number of subjects: 266
Study: 27537530

Group type: EXPERIMENTAL
Intervention: Outpatient management with oral rivaroxaban 15 mg twice daily for 21 days followed by 20 mg once daily for 90 days
Number of subjects: 150

Group type: COMPARATOR
Intervention: Standard care determined by the treating physician and based on local practices
Number of subjects: 150
Study: 24240351

Group type: EXPERIMENTAL
Intervention: 5.0 mg/kg body weight of caffeine dissolved in 200 mL of water
Number of subjects: 41

Group type: COMPARATOR
Intervention: 200 mL of water (placebo)
Number of subjects: 41
Study: 22293063

Group type: EXPERIMENTAL
Intervention: High-soy diet (2 soy food servings/day)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Low-soy diet (<3 servings of soy/wk)
Number of subjects: 82
Study: 19743737

Group type: EXPERIMENTAL
Intervention: Back-mounted hydration systems (BM)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Standard-issue (SI) canteens
Number of subjects: 78
Study: 17234502

Group type: EXPERIMENTAL
Intervention: Intervention group (n = 36) received weekly packets of fruits and vegetables, asked to consume >or=200 g of vegetables and two pieces of fruit daily for 1 month.
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control group (n = 35) did not receive any intervention.
Number of subjects: 71
Study: 15024533

Group type: EXPERIMENTAL
Intervention: Psychotropic medicines use in the two least-educated groups
Number of subjects: 16690

Group type: EXPERIMENTAL
Intervention: Psychotropic medicines use in the two highest educated groups
Number of subjects: 16690

Group type: EXPERIMENTAL
Intervention: Overall patterns of psychotropic medicine use
Number of subjects: 16690
Study: 11779909

Group type: EXPERIMENTAL
Intervention: Traditional Chinese manual acupuncture (35 sessions over 10 weeks)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Standard modalities of treatment (physiotherapy, occupational and speech therapy, skilled medical and nursing care)
Number of subjects: 106
Study: 9819000

Group type: EXPERIMENTAL
Intervention: Reviparin (4200 IU anti-Xa)
Number of subjects: 498

Group type: COMPARATOR
Intervention: Enoxaparin (40mg, approximately 4000 IU anti-Xa)
Number of subjects: 498
Study: 7652635

Group type: EXPERIMENTAL
Intervention: Ketanserin (10 mg IV)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Hydralazine (5 mg IV)
Number of subjects: 20
Study: 2650942

Group type: EXPERIMENTAL
Intervention: Metoprolol 100 mg per os
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 389513

Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg 3 times daily
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg 3 times daily + beta-blocker
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 30922146

Group type: EXPERIMENTAL
Intervention: Bempedoic acid 180 mg once daily for 24 weeks
Number of subjects: 345

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 345
Study: 28182471

Group type: EXPERIMENTAL
Intervention: Cognitive remediation program using computer software (CogPack; Japanese version), administered twice a week for 12 weeks, including a weekly group session.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cognitive remediation program
Number of subjects: 60

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 60
Study: 26376344

Group type: EXPERIMENTAL
Intervention: Peginterferon lambda-1a (Lambda) with ribavirin
Number of subjects: 525
Study: 24276103

Group type: EXPERIMENTAL
Intervention: Intravenous piracetam
Number of subjects: 200

Group type: COMPARATOR
Intervention: Intravenous dimenhydrinate
Number of subjects: 200
Study: 21159432

Group type: EXPERIMENTAL
Intervention: Pain assessment using the pain subscale of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C‐30
Number of subjects: 718

Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) measurement
Number of subjects: 718
Study: 19374740

Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control (Healthy individuals)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both patient groups
Number of subjects: 28
Study: 19681256

Group type: EXPERIMENTAL
Intervention: 6% hydrogen peroxide whitening strips (Crest Whitestrips)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 5.9% hydrogen peroxide paint‐on gel (Colgate Simply White)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Water rinse (negative control)
Number of subjects: 52
Study: 15478912

Group type: EXPERIMENTAL
Intervention: Daclizumab/MMF/Steroids (Tacrolimus started when creatinine dropped below 350 micromol/l)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Tacrolimus/MMF/Steroids
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Delayed introduction of Tacrolimus for machine perfused grafts
Number of subjects: 51
Study: 11675838

Group type: EXPERIMENTAL
Intervention: Heparin 1,000 units/kg
Number of subjects: 38

Group type: COMPARATOR
Intervention: NaCl 0.9% 0.2 mL/kg (Control)
Number of subjects: 38
Study: 9389779

Group type: EXPERIMENTAL
Intervention: 1 gram gel containing 1 mg oestradiol for 3 months plus 20 mg oral MPA during the last 14 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2 g gel containing 2 mg oestradiol for 21 days plus 10 mg oral MPA during the last 14 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2 mg oestradiol valerate tablets for 3 weeks plus 10 mg oral MPA during the last 10 days
Number of subjects: 0
Study: 7701040

Group type: EXPERIMENTAL
Intervention: Buprenorphine (8 mg sublingual, max 16 mg), average dose 11.2 mg
Number of subjects: 51

Group type: COMPARATOR
Intervention: Methadone (50 mg oral, max 90 mg), average dose 66.6 mg
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Buprenorphine and Methadone
Number of subjects: 51
Study: 3115632

Group type: EXPERIMENTAL
Intervention: Melatonin (500 mg at -60 min and at -30 min)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Melatonin (500 mg) prior to GRF 1-44 (1 micrograms/kg i.v. at 0 min)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: COMPARATOR
Intervention: In-vitro basal GH release and GH responses to 10(-8)M GRF by rat anterior pituitary cells
Number of subjects: 8
Study: 28224818

Group type: EXPERIMENTAL
Intervention: Low-dose docosahexaenoic acid (DHA) (260 mg or 520 mg/day)
Number of subjects: 28
Study: 27593174

Group type: EXPERIMENTAL
Intervention: Thrice-weekly insulin degludec (IDeg) injected at twice the once-daily dose before lunch on Monday, Wednesday, and Friday
Number of subjects: 22
Study: 24850107

Group type: COMPARATOR
Intervention: ITM 0.2 mg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: ITM 0.5 mg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: ITM 1 mg
Number of subjects: 90
Study: 23539912

Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Alfentanil
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Nitrous oxide
Number of subjects: 120
Study: 21226953

Group type: EXPERIMENTAL
Intervention: Cilostazol and Probucol combination therapy
Number of subjects: 118

Group type: COMPARATOR
Intervention: Cilostazol monotherapy
Number of subjects: 118
Study: 18316488

Group type: EXPERIMENTAL
Intervention: Transcatheter PFO closure with the STARFlex implant
Number of subjects: 147

Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 147
Study: 16500237

Group type: EXPERIMENTAL
Intervention: Letrozole (Femara)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 0
Study: 14526151

Group type: EXPERIMENTAL
Intervention: Total Enteral Nutrition (TEN)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Total Parenteral Nutrition (TPN)
Number of subjects: 17
Study: 10776008

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (100 mg/d)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 8816539

Group type: COMPARATOR
Intervention: Metal stents (52 patients)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Plastic stents (49 patients)
Number of subjects: 101
Study: 1483490

Group type: EXPERIMENTAL
Intervention: Intracolonic human calcitonin (hCT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous human calcitonin (hCT)
Number of subjects: 0
Study: 3893112

Group type: EXPERIMENTAL
Intervention: Methylprednisolone 2 mg/kg per day intravenously (n = 39)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Cyclosporine (12 to 15 mg/kg per day orally or 3 to 5 mg/kg per day intravenously) (n = 38)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Methylprednisolone
Number of subjects: 77

Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 77
Study: 31382524

Group type: EXPERIMENTAL
Intervention: Beetroot juice (BRJ)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 20
Study: 29746682

Group type: EXPERIMENTAL
Intervention: E-learning course (non-compulsory, 6 weeks duration)
Number of subjects: 356
Study: 26119561

Group type: EXPERIMENTAL
Intervention: Stepwise voltage ramping (n=213)
Number of subjects: 418

Group type: COMPARATOR
Intervention: Fixed maximal voltage (n=205)
Number of subjects: 418
Study: 25102109

Group type: EXPERIMENTAL
Intervention: Multiplex real-time PCR assay
Number of subjects: 0
Study: 22747752

Group type: EXPERIMENTAL
Intervention: Synbiotic formulation (Synbiotic 2000®) containing 4 strains of probiotic bacteria (10^10 each) plus 4 nondigestible, fermentable dietary fibers (2.5 g each) daily for 4 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fiber-only placebo formulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Synbiotic formulation (Synbiotic 2000®)
Number of subjects: 0
Study: 20430604

Group type: EXPERIMENTAL
Intervention: SFC 50/500 microg bd
Number of subjects: 82

Group type: COMPARATOR
Intervention: Fluticasone propionate (FP) 500 microg bd
Number of subjects: 82
Study: 17591479

Group type: EXPERIMENTAL
Intervention: Time-limited fluoroscopy
Number of subjects: 199

Group type: COMPARATOR
Intervention: Continuous fluoroscopy
Number of subjects: 199
Study: 16075172

Group type: EXPERIMENTAL
Intervention: Active ultrasound device
Number of subjects: 22

Group type: COMPARATOR
Intervention: Sham ultrasound device
Number of subjects: 22
Study: 12173195

Group type: EXPERIMENTAL
Intervention: Clonidine 1 microgram kg‐1 added to caudal bupivacaine
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Clonidine 3 micrograms kg‐1 added to caudal bupivacaine
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Clonidine 3 micrograms kg‐1 i.v. and caudal bupivacaine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Caudal block with bupivacaine, no clonidine (control)
Number of subjects: 80
Study: 10390291

Group type: EXPERIMENTAL
Intervention: Low repetition‐heavy load resistance training (1 set of 6 to 8 repetitions, n = 15)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: High repetition‐moderate load resistance training (1 set of 13 to 15 repetitions, n = 16)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (n = 12)
Number of subjects: 43
Study: 8562299

Group type: EXPERIMENTAL
Intervention: Felbamate 1200 mg every 12 h with vigabatrin 1000 mg every 12 h
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Vigabatrin 1000 mg every 12 h with felbamate 1200 mg every 12 h
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 2177368

Group type: EXPERIMENTAL
Intervention: Gliclazide
Number of subjects: 18
Study: 466335

Group type: EXPERIMENTAL
Intervention: Intravenous on-demand fentanyl infusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Epidural injections of bupivacaine
Number of subjects: 0
Study: 31039663

Group type: EXPERIMENTAL
Intervention: Walnut diet (WD)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: All diets (including WD, walnut FA-matched diet, oleic acid-replaced-ALA diet)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Walnut FA-matched diet
Number of subjects: 45
Study: 28468648

Group type: EXPERIMENTAL
Intervention: Counseling plus Expedited Partner Therapy (EPT) with cefixime 400 mg/azithromycin 1 g for up to five recent partners; n=89.
Number of subjects: 173

Group type: COMPARATOR
Intervention: Standard partner notification counseling; n=84.
Number of subjects: 173
Study: 26052700

Group type: EXPERIMENTAL
Intervention: Losartan (100 mg/day)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control (non-treated patients)
Number of subjects: 55
Study: 22664861

Group type: EXPERIMENTAL
Intervention: Rapid enteral feeding advancement (30 mL/kg/d)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Slow enteral feeding advancement (20 mL/kg/d)
Number of subjects: 92
Study: 21654257

Group type: EXPERIMENTAL
Intervention: Any alcohol intake
Number of subjects: 2044

Group type: EXPERIMENTAL
Intervention: Moderate alcohol intake (≤14 g/day)
Number of subjects: 2044

Group type: EXPERIMENTAL
Intervention: Heavy alcohol intake (>14 g/day)
Number of subjects: 2044

Group type: EXPERIMENTAL
Intervention: Moderate beer intake
Number of subjects: 2044

Group type: EXPERIMENTAL
Intervention: Moderate wine intake
Number of subjects: 2044
Study: 19344946

Group type: EXPERIMENTAL
Intervention: Definite Multibond
Number of subjects: 39

Group type: COMPARATOR
Intervention: Syntac/Variolink Ultra
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Both luting systems
Number of subjects: 39
Study: 16762751

Group type: EXPERIMENTAL
Intervention: Color tissue Doppler (TD)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Spectral tissue Doppler (TD)
Number of subjects: 31
Study: 15190794

Group type: EXPERIMENTAL
Intervention: Reverse flaring technique
Number of subjects: 48

Group type: COMPARATOR
Intervention: Step back technique
Number of subjects: 48
Study: 11791759

Group type: EXPERIMENTAL
Intervention: Plasma exchange (PEX)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Drugs only (Control)
Number of subjects: 28
Study: 9781781

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 0
Study: 7730872

Group type: EXPERIMENTAL
Intervention: Age, BMI, and high alcohol consumption
Number of subjects: 3400

Group type: COMPARATOR
Intervention: Other factors (sex, diabetes, triglycerides, HDL cholesterol, height)
Number of subjects: 3400

Group type: EXPERIMENTAL
Intervention: Systolic blood pressure
Number of subjects: 3400

Group type: EXPERIMENTAL
Intervention: Diastolic blood pressure
Number of subjects: 3400
Study: 2648792

Group type: EXPERIMENTAL
Intervention: 100 mg acetylsalicylic acid (ASA) once daily
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 16322122

Group type: EXPERIMENTAL
Intervention: TEW+CT method
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TEW+Chang method
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chang method
Number of subjects: 0

Group type: COMPARATOR
Intervention: xenon CT/CBF method
Number of subjects: 0
Study: 30880405

Group type: EXPERIMENTAL
Intervention: Antidepressants (three types, unspecified)
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: DASS42 anxiety and stress subscales
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: HRSD17 anxiety/somatisation factor
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Common definitions of anxious depression
Number of subjects: 1008
Study: 28467729

Group type: EXPERIMENTAL
Intervention: Exemestane
Number of subjects: 4599

Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 4599

Group type: EXPERIMENTAL
Intervention: Exemestane and Tamoxifen
Number of subjects: 4599
Study: 25554563

Group type: EXPERIMENTAL
Intervention: PF-02545920
Number of subjects: 392

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: Shorter interviews (<15 min)
Number of subjects: 392
Study: 24254033

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Psychoeducation
Number of subjects: 6
Study: 21530211

Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acids (PUFA) 2.4 g
Number of subjects: 56

Group type: COMPARATOR
Intervention: Olive oil
Number of subjects: 56
Study: 19770798

Group type: EXPERIMENTAL
Intervention: PulseCO measurement during optimization of biventricular pacing
Number of subjects: 7

Group type: COMPARATOR
Intervention: Mean arterial pressure measurement
Number of subjects: 7
Study: 16798483

Group type: EXPERIMENTAL
Intervention: Open Lichtenstein's repair
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Laparoscopic totally extraperitoneal hernioplasty
Number of subjects: 37

Group type: COMPARATOR
Intervention: Both interventions (Lichtenstein and laparoscopic hernioplasty)
Number of subjects: 37
Study: 15259326

Group type: EXPERIMENTAL
Intervention: Name cues
Number of subjects: 2

Group type: COMPARATOR
Intervention: Face cues
Number of subjects: 2
Study: 11130217

Group type: EXPERIMENTAL
Intervention: LTG 100 mg with steady‐state BUP 150 mg twice/day
Number of subjects: 12

Group type: COMPARATOR
Intervention: LTG 100 mg
Number of subjects: 12
Study: 9316823

Group type: EXPERIMENTAL
Intervention: ISIS 2302 (0.06-2.00 mg/kg infused over 2 hr)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8287864

Group type: EXPERIMENTAL
Intervention: Allopurinol in the cardioplegic solution
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trimetazidine pre-treatment and addition to the cardioplegic solution
Number of subjects: 0
Study: 3817280

Group type: EXPERIMENTAL
Intervention: Tioconazole cream 1%
Number of subjects: 341

Group type: COMPARATOR
Intervention: Comparative imidazole (econazole or miconazole)
Number of subjects: 341

Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 341
Study: 31784988

Group type: EXPERIMENTAL
Intervention: Intrathecal baclofen (ITB) treatment
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 33
Study: 28723587

Group type: EXPERIMENTAL
Intervention: TeenBP clinical decision support tool (CDS)
Number of subjects: 1214

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 1214
Study: 28744742

Group type: EXPERIMENTAL
Intervention: TCD-11091
Number of subjects: 126

Group type: COMPARATOR
Intervention: non-treatment
Number of subjects: 126
Study: 25465324

Group type: EXPERIMENTAL
Intervention: BMS plus drug coated balloon (DCB)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Bare metal stent (BMS) alone
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: EPC levels
Number of subjects: 20
Study: 23127306

Group type: EXPERIMENTAL
Intervention: oral hygiene instruction and chlorhexidine mouthrinse
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: oral hygiene instruction, chlorhexidine mouthrinse, and assisted brushing
Number of subjects: 102

Group type: COMPARATOR
Intervention: oral hygiene instruction alone
Number of subjects: 102
Study: 21047828

Group type: EXPERIMENTAL
Intervention: NVP200 (nevirapine initiation by dose escalation)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: NVP400 (nevirapine initiation at 200 mg twice daily)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: NVP200
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: NVP400
Number of subjects: 18
Study: 18799723

Group type: EXPERIMENTAL
Intervention: R-CHVP+I (rituximab combined with CHVP and interferon)
Number of subjects: 0

Group type: COMPARATOR
Intervention: CHVP+I (chemotherapy plus interferon)
Number of subjects: 0
Study: 16683297

Group type: EXPERIMENTAL
Intervention: Amniocentesis group
Number of subjects: 254

Group type: COMPARATOR
Intervention: Comparison group (605 women attending routine ultrasound)
Number of subjects: 254
Study: 12885713

Group type: EXPERIMENTAL
Intervention: RTUF
Number of subjects: 70

Group type: COMPARATOR
Intervention: F100
Number of subjects: 70
Study: 10533170

Group type: EXPERIMENTAL
Intervention: Patient education methods in Trial I
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Patient education methods in Trial II
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Patient education methods in Trial III
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Patient SR rate representing a 50% or more decrease in smoking
Number of subjects: 3
Study: 8911858

Group type: EXPERIMENTAL
Intervention: Iloprost infusion
Number of subjects: 60

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 60
Study: 1750722

Group type: EXPERIMENTAL
Intervention: Terfenadine, 120 mg twice a day
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 7127660

Group type: EXPERIMENTAL
Intervention: Oral adjuvant razoxane (ICRF-159)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 176
Study: 30322828

Group type: EXPERIMENTAL
Intervention: Curettage adenoidectomy
Number of subjects: 65

Group type: COMPARATOR
Intervention: Microdebrider adenoidectomy
Number of subjects: 65
Study: 30773689

Group type: EXPERIMENTAL
Intervention: Ethanol lock therapy (ELT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0